BMS explores OS potential of prostate cancer vaccine with $975m deal
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb is paying $60m upfront for an exclusive option to Prostvac, Bavarian Nordic's Phase III-stage prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).